Structural insights into humanization of anti-tissue factor antibody 10H10

ABSTRACT Murine antibody 10H10 raised against human tissue factor is unique in that it blocks the signaling pathway, and thus inhibits angiogenesis and tumor growth without interfering with coagulation. As a potential therapeutic, the antibody was humanized in a two-step procedure. Antigen-binding loops were grafted onto selected human frameworks and the resulting chimeric antibody was subjected to affinity maturation by using phage display libraries. The results of humanization were analyzed from the structural perspective through comparison of the structure of a humanized variant with the parental mouse antibody. This analysis revealed several hot spots in the framework region that appear to affect antigen binding, and therefore should be considered in human germline selection. In addition, some positions in the Vernier zone, e.g., residue 71 in the heavy chain, that are traditionally thought to be crucial appear to tolerate amino acid substitutions without any effect on binding. Several humanized variants were produced using both short and long forms of complementarity-determining region (CDR) H2 following the difference in the Kabat and Martin definitions. Comparison of such pairs indicated consistently higher thermostability of the variants with short CDR H2. Analysis of the binding data in relation to the structures singled out the ImMunoGeneTics information system® germline IGHV1-2*01 as dubious owing to two potentially destabilizing mutations as compared to the other alleles of the same germline and to other human germlines.

[1]  G. Gilliland,et al.  Crystal structure of tissue factor in complex with antibody 10H10 reveals the signaling epitope. , 2017, Cellular signalling.

[2]  Alexey Teplyakov,et al.  Antibody modeling assessment II. Structures and models , 2014, Proteins.

[3]  P. Bowers,et al.  Mammalian cell display and somatic hypermutation in vitro for human antibody discovery. , 2014, Current drug discovery technologies.

[4]  W. Ruf,et al.  Tissue factor and cell signalling in cancer progression and thrombosis , 2011, Journal of thrombosis and haemostasis : JTH.

[5]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[6]  Roland L. Dunbrack,et al.  A new clustering of antibody CDR loop conformations. , 2011, Journal of molecular biology.

[7]  Jinquan Luo,et al.  Antibody Fab display and selection through fusion to the pIX coat protein of filamentous phage. , 2010, Journal of immunological methods.

[8]  Shu Yan Zhang,et al.  A neutron-diffraction study of the low-cycle fatigue behaviour of an austenitic stainless steel 316 , 2010 .

[9]  G. Gilliland,et al.  Promoting crystallization of antibody–antigen complexes via microseed matrix screening , 2010, Acta crystallographica. Section D, Biological crystallography.

[10]  Andrew J. Martin,et al.  Protein Sequence and Structure Analysis of Antibody Variable Domains , 2010 .

[11]  G. Gilliland,et al.  Human framework adaptation of a mouse anti-human IL-13 antibody. , 2010, Journal of molecular biology.

[12]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[13]  A. D'arcy,et al.  An automated microseed matrix-screening method for protein crystallization. , 2007, Acta crystallographica. Section D, Biological crystallography.

[14]  H. Versteeg,et al.  Disulfide isomerization switches tissue factor from coagulation to cell signaling , 2006, Proceedings of the National Academy of Sciences.

[15]  P. Hudson,et al.  Latest technologies for the enhancement of antibody affinity. , 2006, Advanced drug delivery reviews.

[16]  A. Zemla,et al.  Antibody elbow angles are influenced by their light chain class. , 2006, Journal of molecular biology.

[17]  Jérôme Lane,et al.  IMGT®, the international ImMunoGeneTics information system® , 2004, Nucleic Acids Res..

[18]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[19]  M. Holmes,et al.  Structural Effects of Framework Mutations on a Humanized Anti-Lysozyme Antibody1 , 2001, The Journal of Immunology.

[20]  S. Coughlin,et al.  Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[22]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[23]  G. Winter,et al.  Antibody framework residues affecting the conformation of the hypervariable loops. , 1992, Journal of molecular biology.

[24]  A Tramontano,et al.  Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. , 1990, Journal of molecular biology.

[25]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.

[26]  Y. Takada,et al.  Hemostasis, Thrombosis, and Vascular Biology: Inhibition of tissue factor signaling suppresses tumor growth , 2014 .

[27]  E. Kabat,et al.  Sequences of proteins of immunological interest , 1991 .

[28]  P. T. Jones,et al.  Replacing the complementarity-determining regions in a human antibody with those from a mouse , 1986, Nature.